Sociedad Americana de Hirudoterapia

Direction de la Pharmacie et du Médicament — Sénégal

DPM Senegal · Senegal · africa

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Senegal's Directorate of Pharmacy and Medicines (Ministry of Health and Social Action) — leech-specific regulatory pathway has not been independently verified by ASH; medicinal leeches fall under the general national pharmaceutical and medical device framework as appropriate.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
Senegal
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Senegalese Code de la Santé Publique — pharmaceutical and device provisions
  • Senegalese national medical device regulatory framework

Prescriber Requirements

  • Ordre National des Médecins du Sénégal–registered physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

DPM Senegal registration as applicable; French-language labelling (with Wolof at point of dispensing as appropriate). Standard cold-chain conditions.

Import/Export Rules

DPM Senegal and Ministry of Health import authorisation; Direction des Services Vétérinaires clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana.

Reimbursement Context

Not covered under public insurance schemes for leech therapy specifically.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; falls under general medical device / traditional medicine framework as appropriate. Senegal participates in West African Economic and Monetary Union (UEMOA / WAEMU) pharmaceutical harmonisation; whether this harmonisation captures live-organism medical devices has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.